ABBV
Price
$198.79
Change
-$0.07 (-0.04%)
Updated
Aug 8, 02:17 PM (EDT)
Capitalization
322.43B
77 days until earnings call
NVS
Price
$116.87
Change
+$0.95 (+0.82%)
Updated
Aug 8, 03:14 PM (EDT)
Capitalization
197.93B
81 days until earnings call
Interact to see
Advertisement

ABBV vs NVS

Header iconABBV vs NVS Comparison
Open Charts ABBV vs NVSBanner chart's image
ABBVIE
Price$198.79
Change-$0.07 (-0.04%)
Volume$300
Capitalization322.43B
Novartis AG
Price$116.87
Change+$0.95 (+0.82%)
Volume$200
Capitalization197.93B
ABBV vs NVS Comparison Chart in %
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. NVS commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and NVS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (ABBV: $198.86 vs. NVS: $115.92)
Brand notoriety: ABBV: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 82% vs. NVS: 76%
Market capitalization -- ABBV: $322.43B vs. NVS: $197.93B
ABBV [@Pharmaceuticals: Major] is valued at $322.43B. NVS’s [@Pharmaceuticals: Major] market capitalization is $197.93B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 3 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • ABBV’s FA Score: 3 green, 2 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, ABBV is a better buy in the long-term than NVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 3 bullish TA indicator(s).

  • ABBV’s TA Score: 6 bullish, 3 bearish.
  • NVS’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than NVS.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а +5.21% price change this week, while NVS (@Pharmaceuticals: Major) price change was +1.92% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.69%. For the same industry, the average monthly price growth was +6.02%, and the average quarterly price growth was +13.65%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 24, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-0.69% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($322B) has a higher market cap than NVS($198B). ABBV has higher P/E ratio than NVS: ABBV (66.46) vs NVS (23.38). NVS YTD gains are higher at: 23.413 vs. ABBV (14.992). NVS has higher annual earnings (EBITDA): 18.3B vs. ABBV (17.2B). NVS has more cash in the bank: 14B vs. ABBV (12.8B). NVS has less debt than ABBV: NVS (26.3B) vs ABBV (59.4B). ABBV has higher revenues than NVS: ABBV (54.3B) vs NVS (46.7B).
ABBVNVSABBV / NVS
Capitalization322B198B163%
EBITDA17.2B18.3B94%
Gain YTD14.99223.41364%
P/E Ratio66.4623.38284%
Revenue54.3B46.7B116%
Total Cash12.8B14B91%
Total Debt59.4B26.3B226%
FUNDAMENTALS RATINGS
ABBV vs NVS: Fundamental Ratings
ABBV
NVS
OUTLOOK RATING
1..100
7160
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
17
Undervalued
PROFIT vs RISK RATING
1..100
1118
SMR RATING
1..100
1429
PRICE GROWTH RATING
1..100
3457
P/E GROWTH RATING
1..100
1783
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (17) in the Pharmaceuticals Major industry is significantly better than the same rating for ABBV (89). This means that NVS’s stock grew significantly faster than ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is in the same range as NVS (18). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.

ABBV's SMR Rating (14) in the Pharmaceuticals Major industry is in the same range as NVS (29). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.

ABBV's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as NVS (57). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.

ABBV's P/E Growth Rating (17) in the Pharmaceuticals Major industry is significantly better than the same rating for NVS (83). This means that ABBV’s stock grew significantly faster than NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVNVS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
56%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
42%
Bearish Trend 2 days ago
45%
Momentum
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
47%
MACD
ODDS (%)
Bullish Trend 2 days ago
50%
Bearish Trend 2 days ago
43%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
49%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
40%
Advances
ODDS (%)
Bullish Trend 4 days ago
56%
Bullish Trend 5 days ago
49%
Declines
ODDS (%)
Bearish Trend 9 days ago
45%
Bearish Trend 3 days ago
45%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
30%
Bullish Trend 2 days ago
51%
Aroon
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
35%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UVXY15.240.16
+1.06%
ProShares Ultra VIX Short-Term Futures
KBA25.690.12
+0.49%
KraneShares Bosera MSCIChinaA50CntIdETF
USIG51.51-0.06
-0.12%
iShares Broad USD Invm Grd Corp Bd ETF
KJUN26.15-0.04
-0.14%
Innovator U.S. Small Cp Pwr Buf ETF -Jun
GABF46.90-0.29
-0.62%
Gabelli Financial Services Opp ETF